# Development of Population Level Serotyping Technology and Antibody Profiling for Infectious Pathogens with focus on Influenza and SARS-CoV-2

> **NIH NIH R44** · ENCODIA, INC. · 2020 · $728,518

## Abstract

ABSTRACT
The goal of this proposal is to repurpose technology developed for Next-Gen
Proteomics to develop a highly-scalable digital serotyping technology for infectious
disease analysis, with particular application to influenza and Covid-19. The approach is
broadly applicable and should greatly improve upon cost, sensitivity, usability, and
throughput of population-level serotyping and greatly improve infectious disease
monitoring and surveillance.

## Key facts

- **NIH application ID:** 10193123
- **Project number:** 3R44CA203629-03S1
- **Recipient organization:** ENCODIA, INC.
- **Principal Investigator:** Eric Okerberg
- **Activity code:** R44 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $728,518
- **Award type:** 3
- **Project period:** 2016-09-05 → 2022-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10193123

## Citation

> US National Institutes of Health, RePORTER application 10193123, Development of Population Level Serotyping Technology and Antibody Profiling for Infectious Pathogens with focus on Influenza and SARS-CoV-2 (3R44CA203629-03S1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10193123. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*